Singapore, April 18 -- Australia based BlinkLab, a leading digital healthcare startup focused on the development of artificial intelligence (AI)-powered diagnostic technology, has successfully completed an oversubscribed Placement of ordinary shares to sophisticated and institutional investors; raising a total of A$17.5 million (before costs) at a price of A$0.65 per ordinary share.

The successful completion of the Placement represents a critical milestone for BlinkLab as the company advances toward regulatory approval and commercialisation of its lead product, BlinkLab Dx1, a diagnostic aid for the detection of autism.

Published by HT Digital Content Services with permission from BioSpectrum Asia....